NCT06040905 is a NA clinical trial of Coenzyme Q10 in Mild Cognitive Impairment, sponsored by Chung Shan Medical University.

Who is sponsoring NCT06040905?

NCT06040905 is sponsored by Chung Shan Medical University.

What drugs are being tested in NCT06040905?

Interventions in NCT06040905: Coenzyme Q10, Placebo.

What condition does NCT06040905 study?

NCT06040905 studies Mild Cognitive Impairment, Alzheimer Disease, Hyperglycemia, Pre-sarcopenia.

Is NCT06040905 still recruiting?

NCT06040905 is currently recruiting now. Last updated 7 February 2024.

Last reviewed 2024-02-07 · How we verify

NCT06040905

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor

Recruiting now NA Last updated 7 February 2024

What this trial tests

NA trial testing Coenzyme Q10 in Mild Cognitive Impairment in 100 participants. Currently enrolling.

Timeline

26 December 2023

Primary endpoint
31 July 2026

31 July 2026

Quick facts

Lead sponsor	Chung Shan Medical University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	100
Start date	26 December 2023
Primary completion	31 July 2026
Estimated completion	31 July 2026
Sites	1 location across Taiwan

Drugs / interventions tested

Coenzyme Q10 — full drug profile →
Placebo

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Alzheimer Disease — all drugs for Alzheimer Disease →
Hyperglycemia — all drugs for Hyperglycemia →
Pre-sarcopenia — all drugs for Pre-sarcopenia →

Sponsor

Chung Shan Medical University

Who can join

Adults 50 to 80, any sex, with Mild Cognitive Impairment or Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to investigate the effect of coenzyme Q10 supplementation (150 mg/b.i.d, 300 mg/d, 12 weeks) on coenzyme Q10, glucose parameters, BDNF, myokines, and cognitive function in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients who combined with hyperglycemia but without sarcopenia, or with hyperglycemia and pre-sarcopenia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Mitochondrial DNA and Inflammation in Alzheimer's Disease.
Galizzi G, Di Carlo M. · · 2023 · cited 24× · PMID 37998717 · DOI 10.3390/cimb45110540
Type 3 diabetes and metabolic reprogramming of brain neurons: causes and therapeutic strategies.
Meng X, Zhang H, Zhao Z, Li S, et al · · 2025 · cited 19× · PMID 39966707 · DOI 10.1186/s10020-025-01101-z

Verify or expand the search:

Other trials of Coenzyme Q10

Trials testing the same drug.

NCT06743802 — The Effect of Coenzyme Q10 in Preventing Pain After Thoracoscopic Surgery · Phase 4 · recruiting
NCT06856447 — The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Can · Phase 1 · recruiting
NCT07096557 — The Effect of Co-enzyme Q10 on the Clinical Outcome of Pediatric Patients With Systemic Lupus Erythematosus · Phase 2 · completed
NCT05873673 — Coenzyme Q10 and Dentoalveolar Cyst · Phase 2 · active not recruiting
NCT05711810 — Medicine-induced Cardiac Hemodialysis on COVID-19 · Phase 4 · completed

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Other Chung Shan Medical University trials

Trials by the same sponsor.

NCT07443540 — The Effect of Acupuncture on Pulmonary Function Recovery Following Lung Resection · NA · not yet recruiting
NCT07504029 — Human Clinical Trial Evaluating the Blood Glucose-Regulating Effects of Momordica Charantia Peptides · NA · recruiting
NCT07252557 — Mouthwash Temperature and Oral Mucositis in Head and Neck Radiotherapy · NA · not yet recruiting
NCT07282496 — Evaluation of VEDAN RT-90 Resistant Cassava Starch for Glycemic Control and Prebiotic Fiber Development in a Human Trial · NA · not yet recruiting
NCT07504016 — Development of a Novel Cookie Formulation and Evaluation of Its Effects on Glycemic Control in Healthy Individuals · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06040905 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chung Shan Medical University
Last refreshed: 7 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06040905.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing